Prospective, Multicenter Study of the Second Generation Antimicrobial Graft in the Abdominal Position

NCT ID: NCT00824109

Last Updated: 2010-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this prospective trial is to demonstrate the safety and performance of the Second Generation Anti-Microbial vascular graft in the treatment of aneurysmal and occlusive diseases of the abdominal aorta.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aneurysmal Disease of the Abdominal Aorta Occlusive Disease of the Abdominal Aorta

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Aneurysmal disease of the abdominal aorta Occlusive disease of the abdominal aorta

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm Study

Consecutive patients meeting the selection criteria

Group Type OTHER

Second Generation Anti-Microbial bifurcated vascular graft (InterGard)

Intervention Type DEVICE

treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Second Generation Anti-Microbial bifurcated vascular graft (InterGard)

treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

InterGard

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is 18 - 85 years of age
* Is presenting with an aorto-iliac occlusion (obstruction of flow) or stenosis, or aorto-iliac aneurysm and is eligible for a revascularization with a bifurcated graft
* Is affiliated with a social welfare organization system
* Is willing to participate in the clinical evaluation after signature of the informed consent
* Is able to attend all follow up visits and diagnostics and laboratory exams required by the present protocol

Exclusion Criteria

* Is treated as an emergency
* Is included in another investigation
* Is pregnant or lactating, or a woman of childbearing potential unwillint to use an effective form of contraception for the duration of the trial
* Has a known allergy to the material device used
* Has previous aorto-iliac bypass or replacement
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Datascope Corp.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Datascope InterVascular

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Baptiste Ricco, MD

Role: PRINCIPAL_INVESTIGATOR

Vascular Surgery Dept, CHU La Miletrie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU La Miletrie, 350 av. Jacques Coeur

86021 Poitiers, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jean-Baptiste Ricco, MD, Professor

Role: CONTACT

Phone: 00 33 5494438 46

Email: [email protected]

Philippe Bensimon, Director

Role: CONTACT

Phone: 011 33 44 208 7784

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jean-Baptiste Ricco, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HR07-001

Identifier Type: -

Identifier Source: org_study_id